Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 4950 (2021)

Immune thrombocytopenia associated with COVID-19 mRNA vaccine tozinameran – a clinical case and global pharmacovigilance data

  • Raphael Battegay
  • Ioanna Istampoulouoglou
  • Andreas Holbro
  • Andreas Buser
  • Julia R. Hirsiger
  • Jens Eckstein
  • Christoph T. Berger
  • Sarah Koechlin
  • Anne B. Leuppi-Taegtmeyer
DOI
https://doi.org/10.4414/SMW.2021.w30084
Cite this as:
Swiss Med Wkly. 2021;151:w30084
Published
12.12.2021

Summary

We report the occurrence of immune thrombocytopenia (ITP) in a 77-year-old man a few days after receiving the first dose of the COVID-19 mRNA vaccine tozinameran (Comirnaty®). The patient was treated with systemic corticosteroids, intravenous immunoglobulins and eltrombopag. He elected to proceed with the second dose of tozinameran 14 weeks after the first and his platelet count remained stable under a tapered eltrombopag dose. To our knowledge, this is the first case in which a second tozinameran dose has been administered to a patient who developed presumed secondary ITP after the first vaccination. We also report global pharmacovigilance data for the occurrence of ITP after vaccination with tozinameran.

References

  1. Bhattacharjee S, Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. SN Compr Clin Med. 2020 Sep;2(11):1–11. https://doi.org/10.1007/s42399-020-00521-8
  2. Mitta A, Curtis BR, Reese JA, George JN. Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data. Am J Hematol. 2019 Mar;94(3):E76–8.
  3. Product Information Comirnaty®. Pfizer S.A. Switzerland: Zürich; 2021. https://compendium.ch/product/1462602-comirnaty-covid-19-vaccine-inj-konz/mpro#MProproducts (Accessed 2021 January 21).
  4. Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013 Apr;121(14):2596–606. https://doi.org/10.1182/blood-2012-07-442392
  5. Product Information Revolade®. Novartis Pharma S.A. Switzerland: Risch; 2020. https://compendium.ch/product/1152540-revolade-filmtabl-50-mg/mpro#MProproducts (Accessed 2021 May 19).
  6. Lindquist M. VigiBase, the WHO Global ICSR Database System: basic Facts. Drug Inf J. 2008 Sep;42(5):409–19. https://doi.org/10.1177/009286150804200501
  7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577
  8. World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, second edition, 2019 update. Geneva: World Health Organization [Internet]. 2019 [accessed 2021 Jan 22]. Available from: https://www.who.int/vaccine_safety/publications/CausalityAssessmentAEFI_EN.pdf?ua=1
  9. Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol. 2021 May;96(5):E133–4. https://doi.org/10.1002/ajh.26106
  10. Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021 May;96(5):534–7. https://doi.org/10.1002/ajh.26132
  11. Malayala SV, Mohan G, Vasireddy D, Atluri P. Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine. Cureus. 2021 Mar;13(3):e14099. https://doi.org/10.7759/cureus.14099
  12. Helms JM, Ansteatt KT, Roberts JC, Kamatam S, Foong KS, Labayog JS, et al. Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med. 2021 Apr;12:221–4. https://doi.org/10.2147/JBM.S307047
  13. Fueyo-Rodriguez O, Valente-Acosta B, Jimenez-Soto R, Neme-Yunes Y, Inclán-Alarcón SI, Trejo-Gonzalez R, et al. Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination. BMJ Case Rep. 2021 May;14(5):e242220. https://doi.org/10.1136/bcr-2021-242220
  14. Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2021 Jun;39(25):3329–32. https://doi.org/10.1016/j.vaccine.2021.04.054
  15. Dudley MZ, Halsey NA, Omer SB, Orenstein WA, O’Leary ST, Limaye RJ, et al. The state of vaccine safety science: systematic reviews of the evidence. Lancet Infect Dis. 2020 May;20(5):e80–9. https://doi.org/10.1016/S1473-3099(20)30130-4
  16. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019 Oct;28:100766. https://doi.org/10.1016/j.nantod.2019.100766
  17. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010 Mar;85(3):174–80. https://doi.org/10.1002/ajh.21616

Most read articles by the same author(s)

1 2 > >>